Literature DB >> 33284943

A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.

Wenbin Xiao1,2, Linde A Miles2, Robert L Bowman2, Vidushi Durani2, Helen S Tian2, Nicole L DelGaudio2, Tanmay Mishra2, Menglei Zhu3, Yanming Zhang4, Sarah E Stump5, Martin S Tallman6, Ross L Levine2,6, Sheng F Cai2,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33284943      PMCID： PMC7724900          DOI： 10.1182/bloodadvances.2020003326

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  9 in total

1.  Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome.

Authors:  C-Y Chen; L-I Lin; J-L Tang; W Tsay; H-H Chang; Y-C Yeh; C-F Huang; R-J Chiou; M Yao; B-S Ko; Y-C Chen; K-H Lin; D-T Lin; H-F Tien
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

2.  JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

Authors:  Anna Sophia McKenney; Allison N Lau; Amritha Varshini Hanasoge Somasundara; Barbara Spitzer; Andrew M Intlekofer; Jihae Ahn; Kaitlyn Shank; Franck T Rapaport; Minal A Patel; Efthymia Papalexi; Alan H Shih; April Chiu; Elizaveta Freinkman; Esra A Akbay; Mya Steadman; Raj Nagaraja; Katharine Yen; Julie Teruya-Feldstein; Kwok-Kin Wong; Raajit Rampal; Matthew G Vander Heiden; Craig B Thompson; Ross L Levine
Journal:  J Clin Invest       Date:  2018-09-17       Impact factor: 14.808

Review 3.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

4.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

5.  Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

Authors:  Courtney D DiNardo; Eytan M Stein; Stéphane de Botton; Gail J Roboz; Jessica K Altman; Alice S Mims; Ronan Swords; Robert H Collins; Gabriel N Mannis; Daniel A Pollyea; Will Donnellan; Amir T Fathi; Arnaud Pigneux; Harry P Erba; Gabrielle T Prince; Anthony S Stein; Geoffrey L Uy; James M Foran; Elie Traer; Robert K Stuart; Martha L Arellano; James L Slack; Mikkael A Sekeres; Christophe Willekens; Sung Choe; Hongfang Wang; Vickie Zhang; Katharine E Yen; Stephanie M Kapsalis; Hua Yang; David Dai; Bin Fan; Meredith Goldwasser; Hua Liu; Sam Agresta; Bin Wu; Eyal C Attar; Martin S Tallman; Richard M Stone; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2018-06-02       Impact factor: 91.245

6.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

7.  IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.

Authors:  A Tefferi; T Jimma; N H Sulai; T L Lasho; C M Finke; R A Knudson; R F McClure; A Pardanani
Journal:  Leukemia       Date:  2011-09-13       Impact factor: 11.528

8.  Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib.

Authors:  Anand A Patel; Kirk Cahill; Angella Charnot-Katsikas; Hongtao Liu; Sandeep Gurbuxani; Michael Thirman; Satyajit Kosuri; Andrew S Artz; Richard A Larson; Wendy Stock; Jeremy Segal; Olatoyosi Odenike
Journal:  Br J Haematol       Date:  2020-05-01       Impact factor: 8.615

9.  Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.

Authors:  Ritika Dutta; Tian Yi Zhang; Thomas Köhnke; Daniel Thomas; Miles Linde; Eric Gars; Melissa Stafford; Satinder Kaur; Yusuke Nakauchi; Raymond Yin; Armon Azizi; Anupama Narla; Ravindra Majeti
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 19.456
  9 in total
  1 in total

Review 1.  Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenström's Macroglobulinemia-A Particularly Heterogeneous Lymphoma.

Authors:  Ramón García-Sanz; Cristina Jiménez
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.